DSM’s cerclage cable receives FDA clearance for use in orthopedic trauma: 5 notes

The FDA cleared the Dyneema Purity Radiopaque Cerclage Cable by DSM Biomedical, an Exton, Penn.-based developer of biomedical materials and regenerative medicine.

Advertisement

Here are five notes:

 

1. The Dyneema Purity is intended for use in orthopedic trauma treatments.

 

2. The cerclage cable is composed of Dyneema Purity Radiopaque fiber, an ultra-high-molecular-weight polyethylene medical fiber.

 

3. Fifteen times stronger than steel, the fiber demonstrates great flexibility and is biocompatible and chemically inert. The fiber helps decrease tissue inflammation, irrational and metal allergy complications.

 

4. DSM privately collaborated with Maastricht University Medical Center in the Netherlands, to design the cerclage fiber concept.

 

5. “Not only does the FDA clearance facilitate our customers in the launch of their orthopedic trauma devices, it also strengthens the leadership position of Dyneema Purity fiber,” said Carola Hansen, director of biomedical polyethylenes, DSM.

 

More articles on devices:
DJO Global announces financial results for third quarter 2015
5 recent orthopedic, spine device company mergers & acquisitions
Medtech sells two ROSA robotic systems in Georgia, Colorado

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.